在怀孕期间暴露于natalizumab后的疾病活动和新生儿结果
Sandra Thiel1, Nastassja Litvin2, Sabrina Haben2
1Universitätsklinik für Neurologie der Ruhr-Universität Bochum, Katholisches Klinikum Bochum Sankt Josef-Hospital, Bochum, Nordrhein-Westfalen, Germany Sandra.Thiel@ruhr-uni-bochum.de.
Journal of neurology, neurosurgery, and psychiatry
|December 21, 2023
概括
在怀孕30周以后继续使用纳塔利祖马布可以减少产后复发,但会增加新生儿血液学异常 (HA). 这为怀孕期间多发性硬化症管理的风险益处讨论提供了信息.
科学领域:
- 神经学 神经学
- 产科 产科 产科 产科 产科
- 药理学 药理学是指药理学的学科.
背景情况:
- 在怀孕期间停止服用纳塔利祖马布可以引发严重的多发性硬化症复发.
- 第三季度的纳塔利祖马布暴露与新生儿血液学异常 (HA) 有关.
- 在怀孕期间停止纳塔利祖马布的最佳时间仍未确定.
研究的目的:
- 根据怀孕期间停用纳塔利祖马布的时间来比较孕妇和新生儿的结局.
- 评估30个妊娠周 (gw) 后继续使用纳塔利祖马布对复发风险和新生儿健康的影响.
主要方法:
- 对350名暴露于纳塔利祖马布的孕妇进行前性观察队列研究.
- 早期 (<30个月) 和晚期 (≥30个月) 停药组之间的疾病活性和新生儿结局的比较.
- 分析复发率和新生儿并发症,包括血液学异常.
主要成果:
- 持续服用纳塔利祖马布超过30周显著降低了产后复发风险 (25.7%vs62.6%).
- 晚期暴露 (≥30个小时) 与新生儿贫血和血小板缺血的增加有关.
- 对新生儿整体结果没有显著影响,但21.8%的新生儿对于妊娠年龄来说很小.
结论:
- 在30周后继续使用纳塔利祖马布可以降低产后复发风险,但会增加新生儿HA风险.
- 这些发现支持在怀孕期间管理多发性硬化症的风险-益处讨论.
- 停止纳塔利祖马布治疗的最佳时间需要仔细考虑母亲和新生儿的因素.
关键词:
多发性硬化 多发性硬化更多相关视频
08:50A Murine Model of Fetal Exposure to Maternal Inflammation to Study the Effects of Acute Chorioamnionitis on Newborn Intestinal Development
Published on: June 24, 2020
3.8K
07:36Modeling Encephalopathy of Prematurity Using Prenatal Hypoxia-ischemia with Intra-amniotic Lipopolysaccharide in Rats
Published on: November 20, 2015
11.4K
相关概念视频
01:22Development of Immunocompetence
310
The initiation of cell-mediated immunity can be observed as early as the third month of fetal growth, with active antibody-mediated immunity following approximately one month later.
The initial cells that migrate from the fetal thymus settle within the skin and epithelial tissues lining the mouth, digestive tract, and in females, the uterus and vagina. These cells, including skin-based dendritic cells, serve as antigen-presenting cells, playing a key role in T cell activation.
Subsequent T...
The initial cells that migrate from the fetal thymus settle within the skin and epithelial tissues lining the mouth, digestive tract, and in females, the uterus and vagina. These cells, including skin-based dendritic cells, serve as antigen-presenting cells, playing a key role in T cell activation.
Subsequent T...
310
01:07Teratogenicity
2.5K
The ability of a drug to produce structural deformations and functional abnormalities in the developing embryo or the fetus is called teratogenicity, and the drug producing this effect is known as a teratogen. Teratogenic effects include stillbirth, miscarriage, intrauterine growth restriction, and neurocognitive delay. A teratogen may affect the embryo at different stages of development, which is important in determining the type and extent of the damage. During blastocyst formation, the early...
2.5K
01:19Rh Blood Group
1.5K
The Rhesus (Rh) antigen is crucial in determining blood groups and ensuring compatibility during blood transfusions.
1.5K
01:15Transcytosis of IgG
2.8K
Transcytosis is the process in which molecules are internalized by endocytosis, transported across the cell, and released through exocytosis from the opposite end of the cell. Molecules such as insulin, immunoglobulins, and certain nutrients are transferred through the recycling endosomes by recycling and transcytosis.
IgG molecules from a mother undergo transcytosis starting around 13 weeks of gestation. The amount of IgG transferred and entering the fetal blood circulation increases with...
IgG molecules from a mother undergo transcytosis starting around 13 weeks of gestation. The amount of IgG transferred and entering the fetal blood circulation increases with...
2.8K